This case highlights the requirement for <i>ABL1</i> kinase domain mutation analysis in those CML patients on long-term imatinib who lost their molecular response, regardless of whether nonadherence is suspected. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.